GI
PCRX icon

GAMMA Investing’s Pacira BioSciences PCRX Stock Holding History

GAMMA Investing’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.2K Sell
2,371
-460
-16% -$10.9K ﹤0.01% 2177
2026
Q1 		$64K Sell
2,831
-176
-6% -$3.91K ﹤0.01% 2007
2025
Q4 		$77.8K Sell
3,007
-18
-0.6% -$428 ﹤0.01% 1759
2025
Q3 		$78K Sell
3,025
-669
-18% -$16.4K ﹤0.01% 1688
2025
Q2 		$88.3K Hold
3,694
– – 0.01% 1549
2025
Q1 		$91.8K Buy
3,694
+1,958
+113% +$46.9K 0.01% 1333
2024
Q4 		$32.7K Buy
1,736
+179
+11% +$3.14K ﹤0.01% 1986
2024
Q3 		$23.4K Buy
1,557
+219
+16% +$3.74K ﹤0.01% 2014
2024
Q2 		$38.3K Buy
1,338
+932
+230% +$26.5K 0.01% 1381
2024
Q1 		$11.9K Buy
406
+286
+238% +$8.79K ﹤0.01% 1966
2023
Q4 		$3.91K Buy
+120
New +$3.51K ﹤0.01% 2340

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GAMMA Investing's PCRX Position: Q2 2026 in Review

GAMMA Investing reduced its Pacira BioSciences (PCRX) stake by 16% in Q2 2026, selling an estimated $10.9K and leaving 2,371 shares worth $60.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

GAMMA Investing first reported a position in PCRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $91.8K in Q1 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • GAMMA Investing held 2,371 shares of Pacira BioSciences worth $60.2K as of Q2 2026.
  • GAMMA Investing sold 460 Pacira BioSciences shares in Q2 2026, an estimated $10.9K.
  • Pacira BioSciences made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2177 holding.
  • GAMMA Investing first reported a position in Pacira BioSciences in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Pacira BioSciences position peaked at $91.8K in Q1 2025.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.